DRG Epidemiology's coverage of myelodysplastic syndromes comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of myelodysplastic syndromes for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report. In addition to forecasting incident and prevalent patient populations, the number of drug-treatment opportunities at specific lines of therapy are also forecast across the developed world.
DRG Epidemiology's myelodysplastic syndromes forecast will answer the following questions:
In developing countries, what impact will economic growth and development have on the number of people diagnosed with myelodysplastic syndromes per year?
How will improvements in survival change the number of people living with a diagnosis of myelodysplastic syndromes?
Of all people diagnosed with myelodysplastic syndromes, how many in each country across the developed world are drug-treated?
How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of myelodysplastic syndromes over the forecast period?
All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods. In addition, we provide a graphical depiction of the patient flow between or within different disease states for the major mature pharmaceutical markets. These patient flow diagrams are provided at the regional level, but may be requested for any specific country or forecast year.
DRG Epidemiology provides at least ten years of forecast data for the following myelodysplastic syndromes patient populations:
Diagnosed Incidence of Myelodysplastic Syndromes per 100,000 per Year Among People of All Ages in 2020 and 2040ttttttttt
Diagnosed Prevalence of Myelodysplastic Syndromes per 1,000 Among People of All Ages in 2020 and 2040ttttttttt
Relative Sizes of Factors Contributing to the Trend in prevalent cases of Myelodysplastic Syndromes Over the Next Twenty Yearsttttttttt
Analysis of Diagnosed Prevalent Cases of Myelodysplastic Syndromes Across the Countries Under Study in 2020 by IPSS-R Risk
Diagnosed Incident Cases
Diagnosed Prevalent Cases
IPSS and IPSS-R Scores
FLT3 Mutation Status
TP53 Mutation Status
AML Transformation Events
Studies Included in the Analysis of Myelodysplastic Syndromes
Studies Excluded from the Analysis of Myelodysplastic Syndromes
Risk/Protective Factors for Myelodysplastic Syndromes
Ullas Ulahannan, M.P.H., is an associate epidemiologist at Clarivate. Previously, he worked at Jhpiego (a John Hopkins University affiliate) as a senior program officer evaluating, implementing, and monitoring various health programs in collaboration with the state and central governments of India. He earned a B.S. in nursing from Rajiv Gandhi University and an M.P.H. from Manipal University.
Atul Sharma, M.P.H.
Atul Sharma, M.P.H., is an associate epidemiologist at DRG, part of Clarivate. He holds a master’s degree in public health from the School of Public Health, Post-Graduate Institute of Medical Education and Research, and a bachelor’s degree in dental surgery from MN DAV Dental College and Hospital.